Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil

Start: August 2012
End: March 2016
Enrollment: 60

What Is This Study About?

Alzheimer's disease can affect the olfactory bulb and parts of the brain, resulting in difficulty with the sense of smell. Researchers will determine if this difficulty can predict the conversion to Alzheimer's disease in people with amnestic mild cognitive impairment (MCI) and track participants' response to therapy with the Alzheimer's drug donepezil.

Do I Qualify To Participate in This Study?

Minimum Age: 55 Years

Maximum Age: 95 Years

Must have:

  • Amnestic mild cognitive impairment, with subjective memory complaints
  • Wechsler Memory Scale-R Logical Memory combined Story A + B immediate recall score or combined Story A + B delayed recall score; alternatively, Free and Cued Selective Reminding Test immediate recall or delayed recall score; alternatively, Selective Reminding Test immediate recall or delayed recall score, all greater than 1.5 standard deviations below norms
  • Mini Mental State (MMSE) score of at least 23; Clinical Dementia Rating (CDR) of 0.5
  • Availability of study partner

Must NOT have:

  • Dementia based on DSM-IV criteria or probable Alzheimer's disease based on NINCDS-ADRDA criteria
  • Schizophrenia, schizoaffective disorder, other psychosis, or bipolar disorder
  • Alcohol or substance dependence or abuse (current or within past 6 months)
  • Current untreated major depression or suicidality
  • Parkinson's disease, Lewy body disease, multiple sclerosis, central nervous system infection, Huntington's disease, amyotrophic lateral sclerosis, or other major neurological disorder
  • Mental retardation
  • Clinical stroke with residual neurological deficits
  • Acute, severe, unstable medical illness
  • Active cancer; history of successfully treated cancer is acceptable
  • Medical contraindication to donepezil treatment or prior history of intolerability to donepezil treatment
  • Prohibited medications: cholinesterase inhibitors (donepezil, rivastigmine, galantamine), memantine, medications with anticholinergic effects that have been shown to adversely impact cognition, benzodiazepines in lorazepam equivalents greater than or equal to 2 mg daily, narcotics
  • History of anosmia (loss of sense of smell) due to any cause
  • Head trauma with loss of consciousness; nasal sinus disease; current upper respiratory infection; severe allergies to odors; current smoker of more than 1 pack daily

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: New York State Psychiatric Institute

Collaborator Sponsor

  • Department of Defense

Source: ClinicalTrials.gov ID: NCT01845636

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health